Literature DB >> 24445599

Gene silencing associated with SWI/SNF complex loss during NSCLC development.

Shujie Song1, Vonn Walter, Mehmet Karaca, Ying Li, Christopher S Bartlett, Dominic J Smiraglia, Daniel Serber, Christopher D Sproul, Christoph Plass, Jiren Zhang, D Neil Hayes, Yanfang Zheng, Bernard E Weissman.   

Abstract

UNLABELLED: The SWI/SNF chromatin-remodeling complex regulates gene expression and alters chromatin structures in an ATP-dependent manner. Recent sequencing efforts have shown mutations in BRG1 (SMARCA4), one of two mutually exclusive ATPase subunits in the complex, in a significant number of human lung tumor cell lines and primary non-small cell lung carcinoma (NSCLC) clinical specimens. To determine how BRG1 loss fuels tumor progression in NSCLC, molecular profiling was performed after restoration of BRG1 expression or treatment with a histone deacetylase inhibitor or a DNA methyltransferase (DNMT) inhibitor in a BRG1-deficient NSCLC cells. Importantly, validation studies from multiple cell lines revealed that BRG1 reexpression led to substantial changes in the expression of CDH1, CDH3, EHF, and RRAD that commonly undergo silencing by other epigenetic mechanisms during NSCLC development. Furthermore, treatment with DNMT inhibitors did not restore expression of these transcripts, indicating that this common mechanism of gene silencing did not account for their loss of expression. Collectively, BRG1 loss is an important mechanism for the epigenetic silencing of target genes during NSCLC development. IMPLICATIONS: Inactivation of the SWI/SNF complex provides a novel mechanism to induce gene silencing during NSCLC development. Mol Cancer Res; 12(4); 560-70. ©2014 AACR.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24445599      PMCID: PMC3989415          DOI: 10.1158/1541-7786.MCR-13-0427

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  64 in total

Review 1.  Epigenetics of lung cancer.

Authors:  Rayleen V Bowman; Ian A Yang; Annalese B T Semmler; Kwun M Fong
Journal:  Respirology       Date:  2006-07       Impact factor: 6.424

2.  A comparison of background correction methods for two-colour microarrays.

Authors:  Matthew E Ritchie; Jeremy Silver; Alicia Oshlack; Melissa Holmes; Dileepa Diyagama; Andrew Holloway; Gordon K Smyth
Journal:  Bioinformatics       Date:  2007-08-25       Impact factor: 6.937

3.  Restriction landmark genomic scanning: analysis of CpG islands in genomes by 2D gel electrophoresis.

Authors:  Joseph F Costello; Chibo Hong; Christoph Plass; Dominic J Smiraglia
Journal:  Methods Mol Biol       Date:  2009

4.  CpG island hypermethylation profiling of lung cancer using restriction landmark genomic scanning (RLGS) analysis.

Authors:  Jong Park; Romulo Martin Brena; Mike Gruidl; Jun Zhou; Tim Huang; Christoph Plass; Melvyn S Tockman
Journal:  Cancer Biomark       Date:  2005       Impact factor: 4.388

5.  Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines.

Authors:  Pedro P Medina; Octavio A Romero; Takashi Kohno; Luis M Montuenga; Ruben Pio; Jun Yokota; Montse Sanchez-Cespedes
Journal:  Hum Mutat       Date:  2008-05       Impact factor: 4.878

6.  Reduced expression and tumor suppressor function of the ETS transcription factor ESE-3 in prostate cancer.

Authors:  R Cangemi; A Mensah; V Albertini; A Jain; M Mello-Grand; G Chiorino; C V Catapano; G M Carbone
Journal:  Oncogene       Date:  2007-11-26       Impact factor: 9.867

7.  DNA methylation markers and early recurrence in stage I lung cancer.

Authors:  Malcolm V Brock; Craig M Hooker; Emi Ota-Machida; Yu Han; Mingzhou Guo; Stephen Ames; Sabine Glöckner; Steven Piantadosi; Edward Gabrielson; Genevieve Pridham; Kristen Pelosky; Steven A Belinsky; Stephen C Yang; Stephen B Baylin; James G Herman
Journal:  N Engl J Med       Date:  2008-03-13       Impact factor: 91.245

8.  Targeted knockout of BRG1 potentiates lung cancer development.

Authors:  Selina Glaros; Georgina M Cirrincione; Ariel Palanca; Daniel Metzger; David Reisman
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

9.  Characterization of mammary tumors from Brg1 heterozygous mice.

Authors:  S J Bultman; J I Herschkowitz; V Godfrey; T C Gebuhr; M Yaniv; C M Perou; T Magnuson
Journal:  Oncogene       Date:  2007-07-16       Impact factor: 9.867

Review 10.  The BRG1 transcriptional coregulator.

Authors:  Kevin W Trotter; Trevor K Archer
Journal:  Nucl Recept Signal       Date:  2008-02-01
View more
  11 in total

1.  BRG1 regulation by miR-155 in human leukemia and lymphoma cell lines.

Authors:  M Cuadros; V Sánchez-Martín; A Herrera; C Baliñas; J Martín-Padrón; L Boyero; P Peinado; P P Medina
Journal:  Clin Transl Oncol       Date:  2017-03-01       Impact factor: 3.405

2.  A New Chromatin-Cytoskeleton Link in Cancer.

Authors:  Amato J Giaccia
Journal:  Mol Cancer Res       Date:  2016-08-15       Impact factor: 5.852

Review 3.  Epigenomic regulation of oncogenesis by chromatin remodeling.

Authors:  R Kumar; D-Q Li; S Müller; S Knapp
Journal:  Oncogene       Date:  2016-01-25       Impact factor: 9.867

Review 4.  Expanded molecular interrogation for potential actionable targets in non-squamous non-small cell lung cancer.

Authors:  Kah Weng Lau; Claudia Seng; Tony K H Lim; Daniel S W Tan
Journal:  Ann Transl Med       Date:  2017-09

5.  Whole genome expression profiling shows that BRG1 transcriptionally regulates UV inducible genes and other novel targets in human cells.

Authors:  Ling Zhang; Leah Nemzow; Hua Chen; Jennifer J Hu; Feng Gong
Journal:  PLoS One       Date:  2014-08-26       Impact factor: 3.240

6.  Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma.

Authors:  Wei Jiang; Essel Dulaimi; Karthik Devarajan; Theodore Parsons; Qiong Wang; Lili Liao; Eun-Ah Cho; Raymond O'Neill; Charalambos Solomides; Stephen C Peiper; Joseph R Testa; Robert Uzzo; Haifeng Yang
Journal:  PLoS One       Date:  2016-10-20       Impact factor: 3.240

7.  Genome-wide analyses of long noncoding RNA expression profiles in lung adenocarcinoma.

Authors:  Zhenzi Peng; Jun Wang; Bin Shan; Fulai Yuan; Bin Li; Yeping Dong; Wei Peng; Wenwen Shi; Yuanda Cheng; Yang Gao; Chunfang Zhang; Chaojun Duan
Journal:  Sci Rep       Date:  2017-11-10       Impact factor: 4.379

8.  HELLS, a chromatin remodeler is highly expressed in pancreatic cancer and downregulation of it impairs tumor growth and sensitizes to cisplatin by reexpressing the tumor suppressor TGFBR3.

Authors:  Xuyang Hou; Leping Yang; Kunpeng Wang; Yan Zhou; Qinglong Li; Fanhua Kong; Xi Liu; Jun He
Journal:  Cancer Med       Date:  2020-12-06       Impact factor: 4.452

9.  Restoration of BRG1 inhibits proliferation and metastasis of lung cancer by regulating tumor suppressor miR-148b.

Authors:  Zheng Zhou; Yanhe Su; Xianen Fa
Journal:  Onco Targets Ther       Date:  2015-12-02       Impact factor: 4.147

10.  Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma.

Authors:  Hisham Abou-Taleb; Ken Yamaguchi; Noriomi Matsumura; Ryusuke Murakami; Hidekatsu Nakai; Koichiro Higasa; Yasuaki Amano; Kaoru Abiko; Yumiko Yoshioka; Junzo Hamanishi; Masafumi Koshiyama; Tsukasa Baba; Ryo Yamada; Fumihiko Matsuda; Ikuo Konishi; Masaki Mandai
Journal:  Oncotarget       Date:  2016-08-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.